Banglahunt Desk: Clinical trials of this vaccine have started at Oxford University. According to the researchers, the probability of success of this antidote is 80 percent. Researchers from almost all countries of the world have come together at this time. In any case, mankind must be protected from extreme disasters. And so researchers are working day and night to discover the antidote to corona. The University of Oxford is working hard to find a cure for the corona virus. A team is working there under the supervision of virologist Sarah Gilbert. There are two Bengali scientists in that team. Sumi Biswas and Chanda Dutta. Sumi and Chandra are members of the 15-member team that is trying hard to find a cure for corona.
Clinical trials of this vaccine have begun at Oxford University. According to the researchers, the probability of success of this antidote is 80 percent. And so the whole world is now looking at this group of 15 people. Sumi Biswas is an immunologist. After studying microbiology from Bangalore University, he went to Britain. He joined Oxford University after a year at the London School of Hygiene and Tropical Medicine. Sumi Biswas started making malaria antidote at the Jenner Institute seven years ago. He is at the top of the Jenner Institute 6's research team to find a cure for malaria. He is also the Chief Executive Officer of Spybiotech 8, Department of Biochemistry, Oxford University.
Chandra Dutt's house is in the golf garden of Tollygunge. He moved to the UK in 2009 after completing his BTech in Engineering and Biotechnology from the Heritage Institute of Technology. He then did an MSc in Bioscience (Biotechnology) from Leeds University. Join Oxford University's Clinical Biomanufacturing Facility. His responsibility is to monitor the quality of the vaccine. It is Chandra's job to ensure quality assurance. When can the corona vaccine come on the market? Chandra said that as far as I know, the work of making the vaccine will start at the Serum Institute in Pune before the end of the trial. Once the trial is over so that the vaccine can reach the market.